Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: Physicochemical and in vitro pharmaceutical investigations

Journal of Pharmaceutical Sciences

Volumn 103, Issue 9, 2014, Pages 2950-2959

  Yasmin, Rokhsana ^a   Tan, Angel ^a   Bremmell, Kristen E ^a   Prestidge, Clive A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

dissolution; emulsion; lyophilization; nanotechnology; oral drug delivery; silica; solid dosage form

Indexed keywords

AEROSIL; CELECOXIB; CRYOPROTECTIVE AGENT; DRUG CARRIER; SILICA LIPID HYBRID; SILICON DIOXIDE; UNCLASSIFIED DRUG; EMULSION; LIPID; NANOPARTICLE; PYRAZOLE DERIVATIVE; SULFONAMIDE; WATER;

ARTICLE; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; ENCAPSULATION; FEASIBILITY STUDY; FLUORESCENCE IMAGING; FREEZE DRYING; IN VITRO STUDY; PHYSICAL CHEMISTRY; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; CHEMISTRY; EMULSION; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; POROSITY; PROCEDURES; SOLUBILITY;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; EMULSIONS; FREEZE DRYING; LIPIDS; NANOPARTICLES; PARTICLE SIZE; POROSITY; PYRAZOLES; SILICON DIOXIDE; SOLUBILITY; SULFONAMIDES; WATER;

EID: 84906314522     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23914     Document Type: Article

References (39)

1. Humberstone AJ, Charman WN,. 1997. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Del Rev 25 (1): 103-128.
2. MacGregor KJ, Embleton JK, Lacy JE, Perry EA, Solomon LJ, Seager H, Pouton CW,. 1997. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Del Rev 25 (1): 33-46.
3. Chakraborty S, Shukla D, Mishra B, Singh S,. 2009. Lipid-An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 73 (1): 1-15.
4. Simovic S, Heard P, Hui H, Song Y, Peddie F, Davey AK, Lewis A, Rades T, Prestidge CA,. 2009. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs. Mol Pharm 6 (3): 861-872.
5. Pouton CW., 2006. Formulation of poorly water-soluble drugs for oral administration: Physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 29 (3-4 special issue): 278-287.
6. Strickley RG,. Currently marketed oral lipid-based dosage forms: Drug products and excipients. Oral Lipid-Based Formulations: 1-32.
7. Hauss DJ,. 2007. Oral lipid-based formulations. Adv Drug Del Rev 59 (7): 667-676.
8. Jang D-J, Jeong EJ, Lee H-M, Kim B-C, Lim S-J, Kim C-K,. 2006. Improvement of bioavailability and photostability of amlodipine using redispersible dry emulsion. Eur J Pharm Sci 28 (5): 405-411.
9. Dollo G, Le Corre P, Guérin A, Chevanne F, Burgot JL, Leverge R,. 2003. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Sci 19 (4): 273-280.
10. Das S, Chaudhury A,. 2011. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 12 (1): 62-76.
11. Balakrishnan P, Lee B-J, Oh DH, Kim JO, Hong MJ, Jee J-P, Kim JA, Yoo BK, Woo JS, Yong CS, Choi H-G,. 2009. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm 72 (3): 539-545.
12. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H,. 1992. Improvement of photostability of ubidecarenone in the formulation of a novel powdered dosage form termed redispersible dry emulsion. Int J Pharm 86 (1): 25-33.
13. Corveleyn S, Remon JP,. 1998. Formulation of a lyophilized dry emulsion tablet for the delivery of poorly soluble drugs. Int J Pharm 166 (1): 65-74.
14. Pedersen GP, Fäldt P, Bergenståhl B, Kristensen HG,. 1998. Solid state characterisation of a dry emulsion: A potential drug delivery system. Int J Pharm 171 (2): 257-270.
15. Takeuchi H, Sasaki H, Niwa T, Hino T, Kawashima Y, Uesugi K, Ozawa H,. 1991. Redispersible dry emulsion system as novel oral dosage form of oily drugs: In vivo studies in beagle dogs. Chem Pharm Bull 39 (12): 3362-3364.
16. Tan A, Rao S, Prestidge CA,. 2013. Transforming lipid-based oral drug delivery systems into solid dosage forms: An overview of solid carriers, physicochemical properties, and biopharmaceutical performance. Pharm Res: 1-25.
17. Fatouros DG, Karpf DM, Nielsen FS, Mullertz A,. 2007. Clinical studies with oral lipid based formulations of poorly soluble compounds. Ther Clin Risk Manag 3 (4): 591-604.
18. Tan A, Simovic S, Davey AK, Rades T, Prestidge CA,. 2009. Silica-lipid hybrid (SLH) microcapsules: A novel oral delivery system for poorly soluble drugs. J Control Release 134 (1): 62-70.
19. Simovic S, Barnes TJ, Tan A, Prestidge CA,. 2012. Assembling nanoparticle coatings to improve the drug delivery performance of lipid based colloids. Nanoscale 4 (4): 1220-1230.
20. Tan A, Simovic S, Davey AK, Rades T, Boyd BJ, Prestidge CA,. 2010. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems. Mol Pharm 7 (2): 522-532.
21. Simovic S, Heard P, Prestidge CA,. 2010. Hybrid lipid-silica microcapsules engineered by phase coacervation of Pickering emulsions to enhance lipid hydrolysis. Phys Chem Chem Phys 12 (26): 7162-7170.
22. Porter CJH, Pouton CW, Cuine JF, Charman WN,. 2008. Enhancing intestinal drug solubilisation using lipid-based delivery systems. Adv Drug Del Rev 60 (6): 673-691.
23. Nguyen T-H, Tan A, Santos L, Ngo D, Edwards GA, Porter CJH, Prestidge CA, Boyd BJ,. 2013. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation. J Control Release 167 (1): 85-91.
24. Tan A, Martin A, Nguyen T-H, Boyd BJ, Prestidge CA. 2012. Hybrid nanomaterials that mimic the food effect: Controlling enzymatic digestion for enhanced oral drug absorption. Angew Chem Int Ed Engl 51(22):5475-5479.
25. Bremmell KE, Tan A, Martin A, Prestidge CA,. 2013. Tableting lipid-based formulations for oral drug delivery: A case study with silica nanoparticle-lipid-mannitol hybrid microparticles. J Pharm Sci 102 (2): 684-693.
26. Ståhl K, Claesson M, Lilliehorn P, Lindén H, Bäckström K,. 2002. The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int J Pharm 233 (1-2): 227-237.
27. Tan A, Davey A, Prestidge C,. 2011. Silica-lipid hybrid (SLH) versus non-lipid formulations for optimising the dose-dependent oral absorption of celecoxib. Pharm Res 28 (9): 2273-2287.
28. Pharmacopeia US. 2013. The dissolution procedure: Development and validation. US Pharmacopeial Convention, Rockville, Maryland.
29. Sek L, Porter CJH, Kaukonen AM, Charman WN,. 2002. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. J Pharm Pharmacol 54 (1): 29-41.
30. Levine S, Bowen BD, Partridge SJ,. 1989. Stabilization of emulsions by fine particles I. Partitioning of particles between continuous phase and oil/water interface. Colloids Surf 38 (2): 325-343.
31. Guidance for industry. 2000: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. US Food and Drug Administration, Rockville, Maryland.
32. Phan S, Hawley A, Mulet X, Waddington L, Prestidge C, Boyd B,. 2013. Structural aspects of digestion of medium chain triglycerides studied in real time using sSAXS and cryo-TEM. Pharm Res 30 (12): 3088-3100.
33. Berger RI, Klein E, Peterson L, Hunt M, Lever WF,. 1968. The effect of phospholipids on the lipolytic activity of heparin-induced plasma lipase. Life Sci 7 (12, Part 1): 647-651.
34. Klein E, Lyman RB Jr, Peterson L, Berger RI,. 1967. The effect of lecithin on the activity of pancreatic lipase. Life Sci 6 (12): 1305-1307.
35. Porter CJH, Trevaskis NL, Charman WN,. 2007. Lipids and lipid-based formulations: Optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 6 (3): 231-248.
36. Kossena GA, Boyd BJ, Porter CJH, Charman WN,. 2003. Separation and characterization of the colloidal phases produced on digestion of common formulation lipids and assessment of their impact on the apparent solubility of selected poorly water-soluble drugs. J Pharm Sci 92 (3): 634-648.
37. Smirnova I, Suttiruengwong S, Seiler M, Arlt W,. 2005. Dissolution rate enhancement by adsorption of poorly soluble drugs on hydrophilic silica aerogels. Pharm Dev Technol 9 (4): 443-452.
38. Cao X, Fu M, Wang L, Liu H, Deng W, Qu R, Su W, Wei Y, Xu X, Yu J,. 2012. Oral bioavailability of silymarin formulated as a novel 3-day delivery system based on porous silica nanoparticles. Acta Biomater 8 (6): 2104-2112.
39. Thomas N, Holm R, Müllertz A, Rades T,. 2012. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J Control Release 160 (1): 25-32.